文献速递胸部肿瘤放疗

无病理确诊早期NSCLC的SBRT应用与结局:VA队列

Use and Outcomes of SBRT for Early Stage NSCLC Without Pathologic Confirmation in the Veterans Health Care Administration.
PubMed 文献 · Adv Radiat Oncol · 2021-04-20

该研究基于2008至2015年退伍军人医疗系统2221例cT1-T2aN0M0 NSCLC接受SBRT的患者,发现14.9%无病理确诊即治疗,且各中心间差异大(0%-61%)。

要点

  • 无病理确诊SBRT占14.9%,8.8%未尝试活检,各中心差异大(0%-61%)。

核心结论

  • 无病理确诊的经验性SBRT使用在不同机构间差异很大,但合适的影像学检查始终被使用。
  • 无病理确诊组总体生存与病理确诊组相似,但肺癌特异性生存更优。

研究设计与样本

  • 回顾性队列研究,纳入2008至2015年退伍军人医疗系统2221例接受SBRT的cT1-T2aN0M0 NSCLC患者。
  • 比较无病理确诊组与病理确诊组的临床特征、死亡原因及生存,采用Cox比例风险模型。

主要发现

  • 14.9%的患者无病理确诊接受治疗,8.8%未尝试活检。
  • 无病理确诊组中95.5%接受PET扫描,40.6%尝试活检,12.7%接受支气管内超声。
  • 无病理确诊组更常见cT1肿瘤且更少居住在组织胞浆菌病带。

临床怎么用

  • 对于cT1-T2aN0M0 NSCLC,无病理确诊的经验性SBRT是可接受的选择,但需注意机构间差异。
  • 治疗前应进行充分的影像学检查(如PET),并考虑活检尝试。

局限性

  • 研究为回顾性设计,可能存在选择偏倚。
  • 未报告无病理确诊组肺癌特异性生存更优的具体原因。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Stereotactic body radiation therapy (SBRT) use has increased among patients without pathologic confirmation (PC) of lung cancer. Empirical SBRT without PC raises concerns about variation in workup and patient selection, but national trends have not been well described. In this study, we assessed patterns of empirical SBRT use, workup, and causes of death among a large national non-small cell lung cancer (NSCLC) cohort. METHODS AND MATERIALS: We identified 2221 patients treated with SBRT for cT1-T2aN0M0 NSCLC in the Veterans Affairs health care system from 2008 to 2015. We reviewed their pretreatment workup and assessed associations between absence of PC and clinical and demographic factors. We compared causes of death between PC and non-PC groups and used Cox proportional hazards modeling to compare overall survival and lung cancer specific survival (LCSS) between these groups. RESULTS: Treatment without PC varied from 0% to 61% among Veterans Affairs medical centers, with at least 5 cases of stage I NSCLC. Overall, 14.9% of patients were treated without PC and 8.8% did not have a biopsy attempt. Ten percent of facilities were responsible for almost two-thirds (62%) of cases of treatment without PC. Of non-PC patients, 95.5% had positron emission tomography scans, 40.6% had biopsy procedures attempted, and 12.7% underwent endobronchial ultrasound. Non-PC patients were more likely to have cT1 tumors and live outside the histoplasmosis belt. Age, sex, smoking status, and Charlson comorbidity index were similar between groups. Lung cancer was the most common cause of death in both groups. Overall survival was similar between groups, whereas non-PC patients had better LCSS (hazard ratio = 0.77, P = .031). CONCLUSIONS: Empirical SBRT use varied widely among institutions and appropriate radiographic workup was consistently used in this national cohort. Future studies should investigate determinants of variation and reasons for higher LCSS among non-PC patients.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Wilkie JR, Lipson R, Johnson MC, et al. Use and Outcomes of SBRT for Early Stage NSCLC Without Pathologic Confirmation in the Veterans Health Care Administration. Adv Radiat Oncol. 2021. PMID: 34409207. doi:10.1016/j.adro.2021.100707

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。